Sinocelltech

CompanyChina

Sinocelltech develops one asset, in phase 1 (SCT520FF in nAMD). Mostly antibody; based in China.

1
Asset
Furthest stage
Phase 1
21
Trials
0
Signals

Pipeline

1
  • SCT520FF

    Inhibits VEGF-mediated angiogenesis in the retina.

    Phase 1, Antibody, nAMD

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials23
  • Integrity notices1
  • Similar companies6

Intelligence